KDR and metastatic melanoma: An explanation for the (albeit low) activity of sorafenib independent of BRAF inhibition might be explained by the effect of sorafenib on other targets, such as VEGFR2 (which has recently been associated with response to sorafenib given in combination with chemotherapy in metastatic melanoma patients [26]), or c-KIT.